In our cohort, there were similar proportions of triple-negative cancers among metformin users (22%) and nonusers (20%), as well as the same percentage of HER2/neu-positive cancers (16.7%) in each group; however, these numbers were too small for subset analysis. Here, ERBB2 is linked to cancer.